DNp73-induced degradation of tyrosinase links depigmentation with EMT-driven melanoma progression.


Journal

Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053

Informations de publication

Date de publication:
01 02 2019
Historique:
received: 15 08 2018
revised: 30 10 2018
accepted: 07 11 2018
pubmed: 18 11 2018
medline: 2 11 2019
entrez: 17 11 2018
Statut: ppublish

Résumé

Melanoma is an aggressive cancer with poor prognosis, requiring personalized management of advanced stages and establishment of molecular markers. Melanomas derive from melanocytes, which specifically express tyrosinase, the rate-limiting enzyme of melanin-synthesis. We demonstrate that melanomas with high levels of DNp73, a cancer-specific variant of the p53 family member p73 and driver of melanoma progression show, in contrast to their less-aggressive low-DNp73 counterparts, hypopigmentation in vivo. Mechanistically, reduced melanin-synthesis is mediated by a DNp73-activated IGF1R/PI3K/AKT axis leading to tyrosinase ER-arrest and proteasomal degradation. Tyrosinase loss triggers reactivation of the EMT signaling cascade, a mesenchymal-like cell phenotype and increased invasiveness. DNp73-induced depigmentation, Slug increase and changes in cell motility are recapitulated in neural crest-derived melanophores of Xenopus embryos, underscoring a previously unnoticed physiological role of tyrosinase as EMT inhibitor. This data provides a mechanism of hypopigmentation accompanying cancer progression, which can be exploited in precision diagnosis of patients with melanoma-associated hypopigmentation (MAH), currently seen as a favorable prognostic factor. The DNp73/IGF1R/Slug signature in colorless lesions might aid to clinically discriminate between patients with MAH-associated metastatic disease and those, where MAH is indeed a sign of regression.

Identifiants

pubmed: 30445206
pii: S0304-3835(18)30673-6
doi: 10.1016/j.canlet.2018.11.009
pii:
doi:

Substances chimiques

IGF1R protein, human 0
Melanins 0
Reactive Oxygen Species 0
Receptors, Somatomedin 0
Snail Family Transcription Factors 0
TP73 protein, human 0
Tumor Protein p73 0
Monophenol Monooxygenase EC 1.14.18.1
Receptor, IGF Type 1 EC 2.7.10.1
Proteasome Endopeptidase Complex EC 3.4.25.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

299-309

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Katharina Fürst (K)

Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, 18057, Rostock, Germany.

Marc Steder (M)

Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, 18057, Rostock, Germany.

Stella Logotheti (S)

Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, 18057, Rostock, Germany.

Alessandro Angerilli (A)

Biomedical Center Munich, Molecular Biology, Ludwig-Maximilians-University Munich, 82152, Planegg Martinsried, Germany.

Alf Spitschak (A)

Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, 18057, Rostock, Germany.

Stephan Marquardt (S)

Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, 18057, Rostock, Germany.

Toni Schumacher (T)

Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, 18057, Rostock, Germany.

David Engelmann (D)

Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, 18057, Rostock, Germany.

Ottmar Herchenröder (O)

Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, 18057, Rostock, Germany.

Ralph A W Rupp (RAW)

Biomedical Center Munich, Molecular Biology, Ludwig-Maximilians-University Munich, 82152, Planegg Martinsried, Germany.

Brigitte M Pützer (BM)

Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, 18057, Rostock, Germany. Electronic address: brigitte.puetzer@med.uni-rostock.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH